1.
Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/cg15
2.
Type 2 diabetes in adults: management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ng28
3.
Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf
4.
Obesity: identification, assessment and management | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/cg189
5.
Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing. https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/
6.
NHS Evidence: an introduction. http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf
7.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
8.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
9.
Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. 2012;2(11):a007641-a007641. doi:10.1101/cshperspect.a007641
10.
Jelinek HF, Stranieri A, Yatsko A, Venkatraman S. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine. 2016;75:90-97. doi:10.1016/j.compbiomed.2016.05.005
11.
S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes. 2015;5(6). doi:doi: 10.1038/nutd.2015.16
12.
Samuel VT, Shulman GI. Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012;148(5):852-871. doi:10.1016/j.cell.2012.02.017
13.
Beverley M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open. 2015;5(11). doi:doi: 10.1136/bmjopen-2015-009088
14.
Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal. 2016;92(1084):63-69. doi:10.1136/postgradmedj-2015-133281
15.
Anthony H. Barnett, Jenny Grice. New Mechanisms in Glucose Control. BMJ Books; 1 edition; 2013. http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133
16.
Gregg EW. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. Diabetes Care. Published online 10 August 2017. doi:10.2337/dci16-0055
17.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
18.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
19.
Copeland KC, Silverstein J, Moore KR, et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. PEDIATRICS. 2013;131(2):364-382. doi:10.1542/peds.2012-3494
20.
Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. Obstetric Medicine. 2010;3(4). doi:doi: 10.1258/om.2010.100025
21.
Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. Obstetric Medicine. 2009;2(4). doi:doi: 10.1258/om.2009.080049
22.
Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care. 2016;39(2):179-186. doi:10.2337/dc15-1585
23.
Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes. 2015;64(3):673-686. doi:10.2337/db14-0694
24.
Gale EA. Is type 2 diabetes a category error? The Lancet. 2013;381(9881):1956-1957. doi:10.1016/S0140-6736(12)62207-7
25.
Moreno-Castilla C, Mauricio D, Hernandez M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. Current Diabetes Reports. 2016;16(4). doi:10.1007/s11892-016-0717-7
26.
Noctor E, Dunne F. Postnatal testing following gestational diabetes. The Lancet Diabetes & Endocrinology. 2015;3(10):761-762. doi:10.1016/S2213-8587(15)00322-8
27.
Birkeland KI. Hyperglycaemia in pregnancy: still a lot to learn. The Lancet Diabetes & Endocrinology. 2015;3(10):752-753. doi:10.1016/S2213-8587(15)00282-X
28.
Rinki Murphy. Monogenic diabetes and pregnancy. Obstetric Medicine. 2015;8(3). doi:doi: 10.1177/1753495X15590713
29.
Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine. 2016;375(7):644-654. doi:10.1056/NEJMoa1602494
30.
Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3. https://www.nice.org.uk/guidance/ng3
31.
Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine. 2013;30(7):803-817. doi:10.1111/dme.12159
32.
Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care. http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview
33.
Brown J, Alwan NA, West J, et al. Lifestyle interventions for the treatment of women with gestational diabetes. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 1996. doi:10.1002/14651858.CD011970.pub2
34.
Rasouli B, Andersson T, Carlsson PO, et al. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. Diabetic Medicine. 2017;34(9):1259-1263. doi:10.1111/dme.13410
35.
Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Introduction of biosimilar insulins in Europe. Diabetic Medicine. 2017;34(10):1340-1353. doi:10.1111/dme.13400
36.
Perrin NE, Davies MJ, Robertson N, Snoek FJ, Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabetic Medicine. 2017;34(11):1508-1520. doi:10.1111/dme.13448
37.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
38.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
39.
Standards of Medical Care in Diabetes--2015: Summary of Revisions. Diabetes Care. 2015;38(Supplement_1):S4-S4. doi:10.2337/dc15-S003
40.
A Randomised trial of the effect and cost-effectiveness of early intensive mulitfactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diaberes:the anglod-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study. http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract
41.
Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE. 2015;10(9). doi:doi: 10.1371/journal.pone.0135702
42.
Tao L, Wilson ECF, Wareham NJ, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine. 2015;32(7):907-919. doi:10.1111/dme.12711
43.
Gray LJ, Khunti K, Wilmot EG, Yates T, Davies MJ. External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice. 2014;104(3):451-458. doi:10.1016/j.diabres.2014.03.018
44.
Gray LJ, Khunti K, Edwardson C, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia. 2012;55(12):3238-3244. doi:10.1007/s00125-012-2725-8
45.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi:10.2337/dc14-2441
46.
Guidelines. https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes
47.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
48.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
49.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
50.
Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008;336(7642):491-495. doi:10.1136/bmj.39474.922025.BE
51.
Johnston BC, Kanters S, Bandayrel K, et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA. 2014;312(9). doi:10.1001/jama.2014.10397
52.
Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care. 2016;39(5):808-815. doi:10.2337/dc15-1942
53.
Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabetic Medicine. 2015;32(9):1149-1155. doi:10.1111/dme.12722
54.
Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. PLoS ONE. 2013;8(3). doi:doi: 10.1371/journal.pone.0058861
55.
Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 2012;55(3):542-551. doi:10.1007/s00125-011-2403-2
56.
Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes. JAMA. 2011;305(17). doi:10.1001/jama.2011.576
57.
Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care. 2012;35(12):2681-2689. doi:10.2337/dc11-2452
58.
Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. Progress in Cardiovascular Diseases. 2014;56(4):382-390. doi:10.1016/j.pcad.2013.09.002
59.
Qin L, Knol MJ, Corpeleijn E, Stolk RP. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. European Journal of Epidemiology. 2010;25(1):5-12. doi:10.1007/s10654-009-9395-y
60.
Lee IM. Physical Activity and Weight Gain Prevention. JAMA. 2010;303(12). doi:10.1001/jama.2010.312
61.
John M Jakicic. Physical activity considerations for the treatment and prevention of obesity. The American Journal of Clinical Nutrition. 2005;82(1):226S-229S. http://ajcn.nutrition.org/content/82/1/226S
62.
Heinonen I, Helajärvi H, Pahkala K, et al. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. BMJ Open. 2013;3(6). doi:10.1136/bmjopen-2013-002901
63.
Sallis JF, Bull F, Guthold R, et al. Progress in physical activity over the Olympic quadrennium. The Lancet. 2016;388(10051):1325-1336. doi:10.1016/S0140-6736(16)30581-5
64.
Yeh JS, Kushner RF, Schiff GD. Obesity and Management of Weight Loss. New England Journal of Medicine. 2016;375(12):1187-1189. doi:10.1056/NEJMclde1515935
65.
Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. Published online 10 November 2014. https://lra.le.ac.uk/handle/2381/32505
66.
The Eatwell Guide. Public Health England; 2016. https://www.gov.uk/government/publications/the-eatwell-guide
67.
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008. http://www.nice.org.uk/guidance/ta151
68.
Hadjiconstantinou M, Byrne J, Bodicoat DH, et al. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research. 2016;18(10). doi:10.2196/jmir.5991
69.
Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140. Diabetes Care. 2017;40(2):287.1-287. doi:10.2337/dc17-er02
70.
Capehorn M, Polonsky WH, Edelman S, et al. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia ). Diabetic Medicine. Published online March 2017. doi:10.1111/dme.13357
71.
Hartman YAW, Jansen HJ, Hopman MTE, Tack CJ, Thijssen DHJ. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care. 2017;40(9):e120-e121. doi:10.2337/dc17-0787
72.
Hessler DM, Fisher L, Polonsky WH, et al. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabetic Medicine. 2017;34(9):1228-1234. doi:10.1111/dme.13381
73.
Ferrari M, Dal Cin M, Steele M. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. Diabetic Medicine. 2017;34(11):1546-1553. doi:10.1111/dme.13451
74.
William H. Polonsky,Lawrence Fisher,Jay Earles,R. James Dudl,Joel Lees,Joseph Mullan. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Care. http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true
75.
Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey. https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357
76.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
77.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
78.
Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet. 2012;380(9840):475-483. doi:10.1016/S0140-6736(12)60691-6
79.
Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. Archives of Toxicology. 2016;90(8):1861-1881. doi:10.1007/s00204-016-1737-4
80.
Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine. 2007;356(24):2457-2471. doi:10.1056/NEJMoa072761
81.
Tanner M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. Annals of Internal Medicine. 2016;165(4). doi:10.7326/ACPJC-2016-165-4-020
82.
Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2015;109(2):378-388. doi:10.1016/j.diabres.2015.05.025
83.
Bennett WL, Maruthur NM, Singh S, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Annals of Internal Medicine. 2011;154(9). doi:10.7326/0003-4819-154-9-201105030-00336
84.
Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy. 2016;7(3). doi:doi: 10.1007/s13300-016-0189-4
85.
Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy. 2014;5(1). doi:doi: 10.1007/s13300-014-0061-3
86.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
87.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
88.
Ryder B, McKnight J, Blann A, et al. ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes. 2013;30(9):388-391. doi:10.1002/pdi.1816
89.
Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. JAMA. 2007;298(2). doi:10.1001/jama.298.2.194
90.
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet. 2009;374(9683):39-47. doi:10.1016/S0140-6736(09)60659-0
91.
Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE. http://www.nice.org.uk/guidance/PH38
92.
Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 2010;33(6):1255-1261. doi:10.2337/dc09-1914
93.
Buse JB, Bergenstal RM, Glass LC, et al. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine. 2011;154(2). doi:10.7326/0003-4819-154-2-201101180-00300
94.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet. 2010;375(9733):2223-2233. doi:10.1016/S0140-6736(10)60407-2
95.
Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet. 2010;375(9733):2234-2243. doi:10.1016/S0140-6736(10)60406-0
96.
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism. 2007;9(2):194-205. doi:10.1111/j.1463-1326.2006.00704.x
97.
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations
98.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. Published online 15 September 2016. doi:10.1056/NEJMoa1607141
99.
Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology. 2016;4(6):525-536. doi:10.1016/S2213-8587(15)00482-9
100.
Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE. https://www.nice.org.uk/advice/esnm26/chapter/evidence-review
101.
Dapagliflozin in combination therapy for treating type 2 diabetes June 2013. http://www.nice.org.uk/guidance/ta288
102.
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015. https://www.nice.org.uk/guidance/ta248
103.
Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. https://www.nice.org.uk/guidance/ta203
104.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
105.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(18):1797-1799. doi:10.1056/NEJMc1611289
106.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):323-334. doi:10.1056/NEJMoa1515920
107.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 2016;375(18):1799-1802. doi:10.1056/NEJMc1611290
108.
Courtney H, Nayar R, Rajeswaran C, Jandhyala R. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017;Volume 10:79-87. doi:10.2147/DMSO.S126763
109.
Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352
110.
Rotz ME, Ganetsky VS, Sen S, Thomas TF. Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice. 2015;69(5):531-549. doi:10.1111/ijcp.12572
111.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
112.
Levin PA, Nguyen H, Wittbrodt E, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017;Volume 10:123-139. doi:10.2147/DMSO.S130834
113.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
114.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
115.
Leff DR, Heath D. Surgery for obesity in adulthood. BMJ. 2009;339(sep22 1):b3402-b3402. doi:10.1136/bmj.b3402
116.
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine. 2012;366(17):1567-1576. doi:10.1056/NEJMoa1200225
117.
Riddle MC, Aronson R, Home P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489-2496. doi:10.2337/dc12-2454
118.
Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. New England Journal of Medicine. 2004;351(26):2683-2693. doi:10.1056/NEJMoa035622
119.
Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? New England Journal of Medicine. 2016;375(11):1090-1092. doi:10.1056/NEJMcibr1607950
120.
Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. New England Journal of Medicine. 2016;375(11):1054-1067. doi:10.1056/NEJMra1501993
121.
National Obesity Observatory. http://www.noo.org.uk
122.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine. 2017;376(7):641-651. doi:10.1056/NEJMoa1600869
123.
Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews. 2017;33(1). doi:10.1002/dmrr.2818
124.
Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet. 2014;384(9951):1349-1357. doi:10.1016/S0140-6736(14)60976-4
125.
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care. 2014;37(8):2149-2158. doi:10.2337/dc13-2761
126.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine. 2017;376(7):641-651. doi:10.1056/NEJMoa1600869
127.
Bethel MA, Engel SS, Green JB, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care. 2017;40(4):494-501. doi:10.2337/dc16-1135
128.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
129.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
130.
Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine. 2010;363(4):311-320. doi:10.1056/NEJMoa1002853
131.
Choudhary P, Parrott NR, Birtles L, Rutter MK. Islet cell transplantation: current status in the UK (2012). Practical Diabetes. 2012;29(7):280-285. doi:10.1002/pdi.1707
132.
Pickup JC. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. New England Journal of Medicine. 2012;366(17):1616-1624. doi:10.1056/NEJMct1113948
133.
Srinivasan P, Huang GC, Amiel SA, Heaton ND. Islet cell transplantation. Postgraduate Medical Journal. 2007;83(978):224-229. doi:10.1136/pgmj.2006.053447
134.
Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. https://www.nice.org.uk/guidance/ta203
135.
Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine. 2017;34(9):1205-1211. doi:10.1111/dme.13379
136.
Dhatariya KK, Skedgel C, Fordham R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabetic Medicine. 2017;34(10):1361-1366. doi:10.1111/dme.13427
137.
Leelarathna L, Roberts SA, Hindle A, et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabetic Medicine. 2017;34(10):1372-1379. doi:10.1111/dme.13412
138.
Yates T, Davies MJ. Physical activity and Type 1 diabetes: an underused therapy. Diabetic Medicine. 2017;34(11):1498-1499. doi:10.1111/dme.13445
139.
Narendran P, Jackson N, Daley A, et al. Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. Diabetic Medicine. 2017;34(11):1521-1531. doi:10.1111/dme.13439
140.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th ed. John Wiley & Sons, Incorporated; 2016. http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
141.
Holt RIG. Textbook of Diabetes. 4th ed. Wiley-Blackwell; 2010. http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
142.
Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. Journal of diabetes science and technology (Online). 3(4). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/
143.
Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care. 2015;38(8):1583-1591. doi:10.2337/dc15-0279
144.
[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics. http://webarchive.nationalarchives.gov.uk/20080205132320/http:/dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_082200
145.
Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009. https://www.nice.org.uk/guidance/cg76
146.
Grammes J, Stock W, Mann CG, Flynn EM, Kubiak T. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic Medicine. Published online 30 August 2017. doi:10.1111/dme.13506
147.
Sivasubramaniyam S, Amiel SA, Choudhary P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine. 2017;34(10):1456-1460. doi:10.1111/dme.13438
148.
Vloemans AF, van Beers CAJ, de Wit M, et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabetic Medicine. 2017;34(10):1470-1476. doi:10.1111/dme.13429
149.
Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. Diabetes Research and Clinical Practice. 2008;82:S118-S121. doi:10.1016/j.diabres.2008.09.051
150.
Bailey, Stephen. Academic Writing : A Handbook for International Students. http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467
151.
Creme P, Lea MR. Writing At University: A Guide For Students. 3rd ed. McGraw-Hill Education; 2008. https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134
